There have been major advancements in therapies and diagnostics for advanced-stage non-small-cell lung cancer over the past few years and these have led to meaningful increases in survival. One of the biggest advances is in therapeutics and diagnostics for molecular alterations that drive the oncogenic process. Tumor tissue has been the accepted standard biospecimen but there can be limitations with tissue, including collection and analysis. Thus, liquid biopsy, primarily blood plasma, represents a practical alternative source for determining tumor-derived somatic alterations.

This webinar will feature interactive case-based panel discussions to review the state of the field for liquid biopsy in NSCLC and discuss the standard of care recommendations for a global audience that were proposed in the recently published IASLC consensus statement on liquid biopsy. 

This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, pharmacists, patient advocates, and researchers who specialize in diagnostic radiology, pulmonary medicine, medical oncology, thoracic surgery, radiation oncology, pathology, and cancer research/basic sciences.

Upon completion of this activity, the participants should be able to: 

• Review the updated IASLC Consensus Recommendations for the Use of Liquid Biopsy in NSCLC
• Recognize clinical situations when liquid biopsy may improve lung cancer patient outcomes

• David R. Gandara, MD
• Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
• Christian Rolfo, MD, PhD, MBA, Dr.hc.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.